PRESS RELEASE
Late-breaking data were presented today from the investigator-initiated COMPARE trial of 1,800 real-world patients involving Abbott’s market-leading XIENCE V Everolimus Eluting Coronary Stent System and the TAXUS Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS). The results from COMPARE at two years were presented by Peter Smits, M.D., of Maasstad Ziekenhuis, Rotterdam, the Netherlands, during the Cardiovascular Research Foundation’s 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.